Dragonfly, whose co-founders include MIT and UC Berkeley faculty, has boosted its total financing to $300m in round of undisclosed size led by Fidelity.

Dragonfly Therapeutics, a US-based immunotherapy developer exploiting research from Massachusetts Institute of Technology (MIT) and University of California (UC) Berkeley, has increased its overall equity and partnership financing to $300m. The disclosure of its increased total financing follows a round of undisclosed size led by financial services and investment group Fidelity. The company had raised…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.